Stallergenes and DBV Technologies Partner to Develop Birch Pollen Allergy Immunotherapy
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 10 (Table of Contents)
Published: 29 Oct-2013
DOI: 10.3833/pdr.v2013.i10.1987 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Following a May 2013 research alliance between the companies focused on respiratory allergy therapies, immunotherapy specialist Stallergenes has partnered with DBV Technologies to develop and commercialise a treatment for birch pollen allergy using DBV’s Viaskin® epicutaneous drug delivery technology, which modulates the immune response to allergens...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS